SEC 13F Intelligence

Tybourne Capital Management (Hk) Ltd / ZNTL

Tybourne Capital Management (Hk) Ltd’s Zentalis Pharmaceuticals Inc Position

Does Tybourne Capital Management (Hk) Ltd own Zentalis Pharmaceuticals Inc (ZNTL)? Yes — 961.5K shares worth $1M (+4.69% of its 13F portfolio) as of Q3 2025, down from 1.48M shares the prior filed quarter.

Position Value
$1M
Q3 2025
Shares
961.5K
% of Portfolio
+4.69%
Quarters Held
22
currently held

Position History ZNTL

Reported value by quarter
Q2 ’20: $128MQ2 ’20Q3 ’20: $87MQ4 ’20: $138MQ1 ’21: $116MQ1 ’21Q2 ’21: $142MQ3 ’21: $178MQ4 ’21: $221MQ4 ’21Q1 ’22: $112MQ2 ’22: $68MQ3 ’22: $50MQ3 ’22Q4 ’22: $45MQ1 ’23: $28MQ2 ’23: $27MQ2 ’23Q3 ’23: $19MQ4 ’23: $15MQ1 ’24: $15MQ1 ’24Q2 ’24: $4MQ3 ’24: $4MQ4 ’24: $3MQ4 ’24Q1 ’25: $2MQ2 ’25: $2MQ3 ’25: $1MQ3 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2025961.5K$1M+4.69%
Q2 20251.48M$2M+4.96%
Q1 2025961.5K$2M+6.49%
Q4 2024961.5K$3M+0.73%
Q3 2024961.5K$4M+0.99%
Q2 2024961.5K$4M+0.80%
Q1 2024961.5K$15M+2.59%
Q4 2023961.5K$15M+2.17%
Q3 2023961.5K$19M+2.69%
Q2 2023961.5K$27M+2.93%
Q1 20231.63M$28M+2.83%
Q4 20222.23M$45M+4.48%
Q3 20222.30M$50M+4.79%
Q2 20222.43M$68M+4.92%
Q1 20222.43M$112M+6.63%
Q4 20212.63M$221M+6.56%
Q3 20212.66M$178M+4.47%
Q2 20212.66M$142M+2.98%
Q1 20212.66M$116M+2.54%
Q4 20202.66M$138M+2.88%
Q3 20202.66M$87M+2.15%
Q2 20202.66M$128M+3.89%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Tybourne Capital Management (Hk) Ltd’s full portfolio or all institutional holders of ZNTL.